NASDAQ: RNAZ
Transcode Therapeutics Inc Stock Ownership - Who owns Transcode Therapeutics?

Insider buying vs selling

Have Transcode Therapeutics Inc insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when RNAZ insiders and whales buy or sell their stock.

RNAZ Shareholders

What type of owners hold Transcode Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Anna Moore169.34%1,552,785$14.77MInsider
Zdravka Medarova169.34%1,552,785$14.77MInsider
Robert Michael Dudley19.66%180,262$1.71MInsider
Philippe Calais13.89%127,377$1.21MInsider
Thomas A. Fitzgerald6.14%56,318$535.58kInsider
Drw Securities LLC1.28%11,702$111.29kInstitution
Citigroup Inc0.17%1,586$15.08kInstitution
Federation Des Caisses Desjardins Du Quebec0.11%975$9.27kInstitution
Tower Research Capital LLC Trc0.02%142$1.35kInstitution
Sbi Securities Co Ltd0.00%10$95.10Institution

1 of 2

RNAZ vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RNAZ0.41%99.59%
MBIO3.84%10.62%Net Selling
SLXN0.09%99.91%
SONN82.34%17.66%
ACXP2.40%97.60%Net Buying

Transcode Therapeutics Stock Ownership FAQ

Who owns Transcode Therapeutics?

Transcode Therapeutics (NASDAQ: RNAZ) is owned by 1.57% institutional shareholders, 378.37% Transcode Therapeutics insiders, and 0.00% retail investors. Anna Moore is the largest individual Transcode Therapeutics shareholder, owning 1.55M shares representing 169.34% of the company. Anna Moore's Transcode Therapeutics shares are currently valued at $14.77M.

If you're new to stock investing, here's how to buy Transcode Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.